vs
California Resources Corp（CRC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是California Resources Corp的1.1倍（$772.1M vs $679.0M），Revvity净利率更高（12.7% vs 1.8%，领先11.0%），Revvity同比增速更快（5.9% vs -17.8%），Revvity自由现金流更多（$161.8M vs $115.0M），过去两年California Resources Corp的营收复合增速更高（25.8% vs 9.0%）
加州资源集团是一家美国能源企业，主要在加州开展油气勘探业务。公司注册地为特拉华州，总部位于加州长滩，所持有的加州矿产地块面积是该州私有主体中的最高水平。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CRC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$679.0M
营收增速更快
RVTY
高出23.6%
-17.8%
净利率更高
RVTY
高出11.0%
1.8%
自由现金流更多
RVTY
多$46.8M
$115.0M
两年增速更快
CRC
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $679.0M | $772.1M |
| 净利润 | $12.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 6.9% | 14.5% |
| 净利率 | 1.8% | 12.7% |
| 营收同比 | -17.8% | 5.9% |
| 净利润同比 | -63.6% | 3.9% |
| 每股收益（稀释后） | $0.21 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRCRVTY
| Q4 25 | $679.0M | $772.1M | ||
| Q3 25 | $715.0M | $698.9M | ||
| Q2 25 | $702.0M | $720.3M | ||
| Q1 25 | $814.0M | $664.8M | ||
| Q4 24 | $826.0M | $729.4M | ||
| Q3 24 | $870.0M | $684.0M | ||
| Q2 24 | $412.0M | $691.7M | ||
| Q1 24 | $429.0M | $649.9M |
净利润CRCRVTY
| Q4 25 | $12.0M | $98.4M | ||
| Q3 25 | $64.0M | $46.7M | ||
| Q2 25 | $172.0M | $53.9M | ||
| Q1 25 | $115.0M | $42.2M | ||
| Q4 24 | $33.0M | $94.6M | ||
| Q3 24 | $345.0M | $94.4M | ||
| Q2 24 | $8.0M | $55.4M | ||
| Q1 24 | $-10.0M | $26.0M |
毛利率CRCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CRCRVTY
| Q4 25 | 6.9% | 14.5% | ||
| Q3 25 | 13.7% | 11.7% | ||
| Q2 25 | 38.0% | 12.6% | ||
| Q1 25 | 22.9% | 10.9% | ||
| Q4 24 | 8.2% | 16.3% | ||
| Q3 24 | 59.5% | 14.3% | ||
| Q2 24 | 9.2% | 12.4% | ||
| Q1 24 | -0.9% | 6.8% |
净利率CRCRVTY
| Q4 25 | 1.8% | 12.7% | ||
| Q3 25 | 9.0% | 6.7% | ||
| Q2 25 | 24.5% | 7.5% | ||
| Q1 25 | 14.1% | 6.4% | ||
| Q4 24 | 4.0% | 13.0% | ||
| Q3 24 | 39.7% | 13.8% | ||
| Q2 24 | 1.9% | 8.0% | ||
| Q1 24 | -2.3% | 4.0% |
每股收益（稀释后）CRCRVTY
| Q4 25 | $0.21 | $0.86 | ||
| Q3 25 | $0.76 | $0.40 | ||
| Q2 25 | $1.92 | $0.46 | ||
| Q1 25 | $1.26 | $0.35 | ||
| Q4 24 | $0.87 | $0.77 | ||
| Q3 24 | $3.78 | $0.77 | ||
| Q2 24 | $0.11 | $0.45 | ||
| Q1 24 | $-0.14 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $132.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.7B | $7.3B |
| 总资产 | $7.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRCRVTY
| Q4 25 | $132.0M | $919.9M | ||
| Q3 25 | $196.0M | $931.4M | ||
| Q2 25 | $72.0M | $991.8M | ||
| Q1 25 | $214.0M | $1.1B | ||
| Q4 24 | $372.0M | $1.2B | ||
| Q3 24 | $241.0M | $1.2B | ||
| Q2 24 | $1.0B | $2.0B | ||
| Q1 24 | $403.0M | $1.7B |
总债务CRCRVTY
| Q4 25 | — | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $541.0M | — |
股东权益CRCRVTY
| Q4 25 | $3.7B | $7.3B | ||
| Q3 25 | $3.4B | $7.4B | ||
| Q2 25 | $3.4B | $7.6B | ||
| Q1 25 | $3.5B | $7.6B | ||
| Q4 24 | $3.5B | $7.7B | ||
| Q3 24 | $3.5B | $7.9B | ||
| Q2 24 | $2.1B | $7.9B | ||
| Q1 24 | $2.1B | $7.8B |
总资产CRCRVTY
| Q4 25 | $7.4B | $12.2B | ||
| Q3 25 | $6.8B | $12.1B | ||
| Q2 25 | $6.7B | $12.4B | ||
| Q1 25 | $6.8B | $12.4B | ||
| Q4 24 | $7.1B | $12.4B | ||
| Q3 24 | $7.1B | $12.8B | ||
| Q2 24 | $4.5B | $13.4B | ||
| Q1 24 | $3.9B | $13.4B |
负债/权益比CRCRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.26× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $235.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $115.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 16.9% | 21.0% |
| 资本支出强度资本支出/营收 | 17.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 19.58× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $543.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CRCRVTY
| Q4 25 | $235.0M | $182.0M | ||
| Q3 25 | $279.0M | $138.5M | ||
| Q2 25 | $165.0M | $134.3M | ||
| Q1 25 | $186.0M | $128.2M | ||
| Q4 24 | $206.0M | $174.2M | ||
| Q3 24 | $220.0M | $147.9M | ||
| Q2 24 | $97.0M | $158.6M | ||
| Q1 24 | $87.0M | $147.6M |
自由现金流CRCRVTY
| Q4 25 | $115.0M | $161.8M | ||
| Q3 25 | $188.0M | $120.0M | ||
| Q2 25 | $109.0M | $115.5M | ||
| Q1 25 | $131.0M | $112.2M | ||
| Q4 24 | $118.0M | $149.8M | ||
| Q3 24 | $141.0M | $125.6M | ||
| Q2 24 | $63.0M | $136.6M | ||
| Q1 24 | $33.0M | $129.7M |
自由现金流率CRCRVTY
| Q4 25 | 16.9% | 21.0% | ||
| Q3 25 | 26.3% | 17.2% | ||
| Q2 25 | 15.5% | 16.0% | ||
| Q1 25 | 16.1% | 16.9% | ||
| Q4 24 | 14.3% | 20.5% | ||
| Q3 24 | 16.2% | 18.4% | ||
| Q2 24 | 15.3% | 19.7% | ||
| Q1 24 | 7.7% | 20.0% |
资本支出强度CRCRVTY
| Q4 25 | 17.7% | 2.6% | ||
| Q3 25 | 12.7% | 2.6% | ||
| Q2 25 | 8.0% | 2.6% | ||
| Q1 25 | 6.8% | 2.4% | ||
| Q4 24 | 10.7% | 3.4% | ||
| Q3 24 | 9.1% | 3.3% | ||
| Q2 24 | 8.3% | 3.2% | ||
| Q1 24 | 12.6% | 2.7% |
现金转化率CRCRVTY
| Q4 25 | 19.58× | 1.85× | ||
| Q3 25 | 4.36× | 2.97× | ||
| Q2 25 | 0.96× | 2.49× | ||
| Q1 25 | 1.62× | 3.03× | ||
| Q4 24 | 6.24× | 1.84× | ||
| Q3 24 | 0.64× | 1.57× | ||
| Q2 24 | 12.13× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRC
| Oil And Natural Gas Segment | $645.0M | 95% |
| Natural Gas Production | $26.0M | 4% |
| Other | $7.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
